Varenicline Can Be Prescribed to Patients with Bipolar Disorder, But Requires Close Monitoring
Varenicline is safe to prescribe to patients with stable bipolar disorder who are motivated to quit smoking, but requires vigilant monitoring for neuropsychiatric adverse events including mood destabilization, suicidal ideation, and psychotic symptoms. 1
Evidence Supporting Use in Bipolar Disorder
The strongest evidence comes from a 2014 randomized, double-blind, placebo-controlled trial specifically in euthymic bipolar patients. This study demonstrated that varenicline was significantly more effective than placebo (48.4% vs 10.3% quit rate at 3 months) in clinically stable bipolar patients, with psychopathology scores remaining stable throughout treatment 2. This is the highest-quality study directly addressing your question.
A 2022 clinical practice guideline on bipolar disorder with comorbid substance use weakly recommends varenicline to improve nicotine abstinence in this population 3. Additionally, a 2016 expert review concluded that varenicline can be used in patients with stable psychiatric disease when safety is ensured through close clinical monitoring 4.
FDA Warnings and Monitoring Requirements
The FDA label contains important warnings that must be considered 1:
- Serious neuropsychiatric adverse events have been reported, including depression, mania, psychosis, hallucinations, paranoia, delusions, aggression, hostility, anxiety, suicidal ideation, and completed suicide
- Some patients experienced worsening of pre-existing psychiatric illnesses
- Patients and caregivers must be instructed to immediately stop varenicline and contact healthcare provider if agitation, depressed mood, behavioral changes, or suicidal ideation develop
However, the large postmarketing neuropsychiatric safety trial showed that in the psychiatric cohort, serious neuropsychiatric events occurred in only 0.6% of varenicline-treated patients 1.
Critical Caveats and Case Reports
While the controlled trial data is reassuring, case reports document varenicline-induced mania and psychotic symptoms in bipolar patients 5, 6. One case described auditory hallucinations, paranoia, and referential beliefs developing shortly after varenicline initiation 5. Another documented a manic episode triggered by varenicline 6.
A 2023 survey found that 43% of providers indicated they would be unlikely to use varenicline in patients with bipolar disorder, suggesting ongoing clinical hesitancy despite available evidence 7.
Clinical Algorithm for Safe Prescribing
Prerequisites before prescribing:
- Patient must be clinically stable/euthymic (not currently manic, hypomanic, or depressed)
- Patient must be on stable mood stabilizer regimen
- Patient must be motivated to quit smoking
- Establish baseline mood symptoms and psychotic symptom assessment
Monitoring protocol:
- Weekly visits during the first month of treatment
- Assess for: mood elevation/depression, irritability, agitation, anxiety, sleep changes, psychotic symptoms, suicidal ideation
- Continue monitoring every 2 weeks through treatment completion
- Immediately discontinue if any neuropsychiatric symptoms emerge
Dosing:
- Use standard FDA titration: 0.5 mg once daily for 3 days, then 0.5 mg twice daily for 4 days, then 1 mg twice daily 1
- Consider lower maintenance doses (0.5-1.3 mg/day) if tolerability concerns arise 8
Duration:
- Standard 12-week course initially
- Consider maintenance therapy beyond 12 weeks, as evidence shows bipolar patients have higher relapse rates without continued treatment 9
Bottom Line
The controlled trial evidence supports varenicline use in stable bipolar disorder with appropriate monitoring, outweighing the case report concerns when patients are carefully selected and monitored. The alternative—continued smoking—carries far greater morbidity and mortality risk than the potential psychiatric adverse effects of varenicline.